News

A modifier gene called SLC26A9 may have an influence on whether or not cystic fibrosis (CF) patients will respond to treatments with new drugs.

The abundant mucus in the lungs of cystic fibrosis (CF) patients helps certain types of bacteria, called anaerobes, to survive and, in turn, support the survival and proliferation of more dangerous opportunistic pathogens like Pseudomonas aeruginosa, which otherwise would not find the nutrients they need in mucus-lined airways, a study reported. This symbiotic…

Sophia Genetics and Devyser announced a partnership to simplify the adoption of next-generation DNA sequencing (NGS) for routine diagnostic laboratories. According to the terms of the agreement, Sophia Genetics will use its advanced analytical platform, Sophia DDM, to support Devyser’s NGS diagnostic kits for cystic fibrosis (Devyser CFTR) and hereditary breast…

The Journal of Innate Immunity published three studies that reviewed several central questions about lung disease in cystic fibrosis (CF). The reviews, prepared by three international opinion research leaders in the field, attempt to shed light on some still unclear aspects of this disease. These reviews “will help to consolidate…

To become biologically active, most proteins must acquire a defined three-dimensional structure in processes that are mediated and monitored by molecular chaperones. Researchers based in Germany and the U.S., possibly for a first time,  have revealed how these chaperones identify particularly harmful errors in protein conformation, and induce their degradation. The…

Kary Coleman, director of development and alumni relations at Penn State University’s New Kensington campus, was honored as one of Pittsburgh’s 50 Finest in 2016 by  WHIRL Magazine and the Cystic Fibrosis Foundation (CFF) of Western Pennsylvania for raising more than $6,000 in six months — 153 percent of the…

Spyryx Biosciences recently announced that Dr. Alistair Wheeler is joining the company as its new chief medical officer. Spyryx, a clinical-stage biopharma specializing in therapeutics for respiratory diseases, is currently evaluating a potential treatment for cystic fibrosis (CF) in early clinical testing. Wheeler will be responsible for all aspects of clinical and medical processes and associated regulatory…

The cystic fibrosis transmembrane conductance regulator (CFTR), a key protein that is defective in people with cystic fibrosis, is abundant in the gastrointestinal tract of people and may be a reason why CF patients are troubled by gastrointestinal problems, a recent collaborative study by researchers at Peking University Health Science Center and Shantou…

ProQR Therapeutics announced that it plans to announce proof-of-concept results from tests of its lead candidate to treat cystic fibrosis (CF), QR-010, at a scientific conference this year, and is continuing to advance the development of this and other transformative RNA medicines for severe orphan diseases like CF and Leber’s…

Pulmatrix‘s inhaled PUR1900 for treating pulmonary fungal infections in patients with cystic fibrosis(CF) has received orphan drug status by the U.S. Food and Drug Administration (FDA). The designation was granted “based on a plausible hypothesis that (PUR1900) may be clinically superior to the same drug that is already approved for the same…